BLGO:OTCQX

BioLargo Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over thirteen years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries.

With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets.

BLGO:OTCQX

View Company News

Visit Company Website

BioLargo Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page. Please refer to the important disclosures below for additional details.

Co. Prepares to Roll Out Wound Irrigating Solution

Research Report

Richard Ryan (05/21/2025)

BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report.

Tags: Biotechnology / Pharmaceuticals

Environmental Firm Delivers Cost-Saving Water Technology Solution

Streetwise Reports (05/08/2025)

Clean technology company BioLargo Inc. (BLGO:OTCQX) announced case study data on the cost savings of its Aqueous Electrostatic Concentrator (AEC) solution for removing "forever chemicals" from water. Read why one analyst says you shouldn't pass this stock by.

Richard Ryan, Oak Ridge Financial (5/19/25) "BioLargo Inc. has regulatory approval for its wound irrigation solution to be used across multiple areas, a large market opportunity exists, it has signed partnering agreements and all participants are working toward commercial launch. . .we believe Clyra has a chance to be one of the most impactful and profitable operations for BioLargo."

Richard Ryan, Oak Ridge Financial (4/3/25) "We believe that newsworthy events are likely within several of BioLargo Inc.'s segments in the relatively near term, that a rewrite of the story is at hand. Next up for potential commercialization are the company's wound-healing irrigation solution (U.S. Food and Drug Administration-certified Bioclynse) and its novel PFAS treatment technology, which is on the cusp of having its first municipal project underway."

Richard Ryan, Oak Ridge Financial (11/18/24) "BioLargo Inc. announced Q3/24 revenues that again showed strong year over year growth. . .revenues were $4.4M, up from $2.7M a year ago. . .the company's balance sheet remains solid."

Gowshihan Sriharan, Singular Research (8/30/24) "BioLargo Inc. delivered 247% year-over-year revenue growth in Q2/24, ahead of our estimates. Pooph revenue continues to grow rapidly, and the company's first PFAS remediation project is on track for completion by Q4/24. We are bullish on BioLargo's long-term prospects."

Richard Ryan, Oak Ridge Financial (8/16/24) "BioLargo Inc. announced Q2/24 revenues that again showed strong year-over-year and modest quarter-over-quarter growth. Revenues were $5M, up from $1.4M a year ago and up 5% sequentially as Pooph sales saw continued good performance."

Richard Ryan, Oak Ridge Financial (5/16/24) "BioLargo Inc. announced Q1/24 revenues that again showed strong year-over-year and quarter-over-quarter growth. The company generated positive cash flow from operations and increased its shareholders' equity to $5.1M, all while maintaining minimal debt and ending the quarter with $4.3M in cash."

Richard Ryan, Oak Ridge Financial (4/17/24) "The final PFAS regulations from the Environmental Protection Agency validate BioLargo Inc.'s water treatment vision. . .under the new rule, water utilities must monitor PFAS chemicals and would be required to notify the public and reduce contamination if levels exceeded the new standard. . .the large emerging market for PFAS removal and the company's growing validation in this opportunity should not be overlooked."

Richard Ryan, Oak Ridge Financial (4/4/24) "BioLargo Inc. announced that 2023 revenues more than doubled the level the company reported in 2022, making it the second year in a row that revenues have grown at that rate. BioLargo maintained gross margin at 50%, doubled shareholders' equity, all while maintaining minimal debt and ending the year with $3.5M in cash."

Clive Maund, CliveMaund.com (2/14/24) "The fundamentals of BioLargo Inc. are superb with everything coming together in a positive manner after many years of work. So ultimately, the company's stock is believed headed much higher."

Richard Ryan, Oak Ridge Financial (1/29/24) "BioLargo Inc. announced that its 2023 revenues more than doubled the level it reported in 2022, making it the second year in a row that revenues have grown at that rate. . .the company's results continue to be driven by Pooph sales, its pet odor control product line that is being sold through national retailers like Amazon, Walmart, Chewy and a growing list of other retailers."

Clive Maund, CliveMaund.com (1/25/24) "Over the past couple of days after a steep advance, BioLargo Inc. has reacted back a shade. But the dramatic dieback in volume is bullish and suggests that this steep uptrend is not done yet."

Clive Maund, CliveMaund.com (12/22/23) "BioLargo Inc. is at a good entry point here, and the company is rated a Strong Conservative Buy for all time frames. . .it is considered to have substantial upside from here with the capacity to make faster gains than many consider possible, especially if there is anything to the sodium battery story."

Richard Ryan, Oak Ridge Financial (12/8/23) "BioLargo Inc. has finished its rollout of Pooph into Walmart locations and expects that Ikigai, its major distribution partner, can secure contracts for more than 20K retail stores by 2023E. . .Pooph appears to be on the cusp for significant revenue expansion, which has been reaffirmed through Amazon as Pooph averages over 90K bottles purchased each month (as of Dec. 7, 2023) with a Best Seller ranking of No. 1 in Dog Deodorizers."

Richard Ryan – Oak Ridge Financial
Gowshihan Sriharan – Singular Research
	Chris Temple, Editor and Publisher – The National Investor

	Invest-prove-partner business model that leverages credible partners to maximize impact
	Unrivaled technologies to solve challenges in emerging environmental markets
	Heading toward profitability, with average QoQ revenue growth of +25% over past two years

Recent Articles:

More Articles

Expert Comments:

Richard Ryan, Oak Ridge Financial

Richard Ryan, Oak Ridge Financial

Richard Ryan, Oak Ridge Financial

Gowshihan Sriharan, Singular Research

Richard Ryan, Oak Ridge Financial

More Expert Comments

Richard Ryan, Oak Ridge Financial

Richard Ryan, Oak Ridge Financial

Richard Ryan, Oak Ridge Financial

Clive Maund, CliveMaund.com

Richard Ryan, Oak Ridge Financial

Clive Maund, CliveMaund.com

Clive Maund, CliveMaund.com

Richard Ryan, Oak Ridge Financial

Experts Following This Company

Company News

Streetwise - BioLargo Inc. Ownership Overview*